Related Experiment Video
Updated: Feb 11, 2026

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry
Published on: September 1, 2019
CMPD1 inhibited human gastric cancer cell proliferation by inducing apoptosis and G2/M cell cycle arrest
Yu Li1,2, Depeng Zhang3, Kaikai Yu3
1Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Bengbu, 233004, Anhui, People's Republic of China.
Background:
Gastric cancer occupies the fourth highest morbidity rate of cancers worldwide. Clinical therapies of gastric cancer remain limited because of uncertainty of mechanisms and shortness of effective medicine. Thus, new drug candidates for gastric cancer treatment is urgently needed.
Results:
In this study, CMPD1 as a wildly used MK2 phosphorylation inhibitor was employed to find its impact on gastric cancer cell proliferation, apoptosis and cell cycle using colony formation assay and flow cytometry analysis. Along with its anti-proliferation effect on gastric cancer cell line MKN-45 and SGC7901, CMPD1 also induced massive apoptosis and significant G2/M phase arrest in a time-dependent and dose-dependent manner in MKN-45 cells respectively. Furthermore, Western blot confirmed that the expression of anti-apoptotic proteins Bcl-2 was decreased while BAX, cytochrome c release and cleaved PARP were increased. In addition, oncogene c-Myc was downregulated in response to CMPD1 treatment.
Conclusions:
Our results demonstrated that CMPD1 has anti-tumor effect on human gastric cancer cell line MKN-45 possibly via downregulating oncogene c-Myc expression and CMPD1 could be applied as a potential candidate for treating gastric malignancy. To the best of our knowledge, it is the first report of anti-tumor effect of CMPD-1 on human gastric cancer cells.
Insights
CMPD1, a p38 mitogen-activated protein kinase 2 (MK2) inhibitor, demonstrates significant anti-tumor effects against gastric cancer. It effectively reduces cell proliferation, induces apoptosis, and arrests cell cycle progression in gastric cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Gastric cancer is a leading cause of cancer morbidity globally.
- Current therapeutic options for gastric cancer are limited due to unclear mechanisms and lack of effective drugs.
- Novel therapeutic agents are urgently required for gastric cancer treatment.
Purpose of the Study:
- To investigate the anti-tumor effects of CMPD1, a known MK2 phosphorylation inhibitor, on human gastric cancer cells.
- To determine the impact of CMPD1 on gastric cancer cell proliferation, apoptosis, and cell cycle.
- To explore the underlying molecular mechanisms of CMPD1's anti-cancer activity.
Main Methods:
- Colony formation assay to assess cell proliferation.
- Flow cytometry analysis to evaluate apoptosis and cell cycle.
- Western blot analysis to examine protein expression levels.
Main Results:
- CMPD1 exhibited anti-proliferative effects on gastric cancer cell lines MKN-45 and SGC7901.
- CMPD1 induced significant apoptosis and G2/M phase arrest in MKN-45 cells in a dose- and time-dependent manner.
- CMPD1 treatment led to decreased Bcl-2 expression and increased BAX, cytochrome c release, and cleaved PARP.
- The expression of the oncogene c-Myc was downregulated by CMPD1.
Conclusions:
- CMPD1 demonstrates potent anti-tumor activity against human gastric cancer cells, specifically the MKN-45 cell line.
- The anti-tumor effect is potentially mediated by the downregulation of the oncogene c-Myc.
- CMPD1 represents a promising candidate for the development of novel gastric cancer therapeutics.
More Related Videos
Related Concept Videos
What is the Cell Cycle?
What is the Cell Cycle?
Cells Coordinate Growth and Proliferation
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System
Mitogens and the Cell Cycle

